ORLYNVAH™ (sulopenem)

About Iterum Therapeutics

Iterum Therapeutics is an Irish biopharmaceutical company with a mission to develop differentiated antibiotics against multi-drug resistant pathogens. Its core achievement is the 2024 FDA approval of ORLYNVAH™ (sulopenem), the first oral penem, for uncomplicated urinary tract infections (uUTI) in patients with limited treatment options. The company's strategy leverages the unique oral/IV profile of sulopenem to address serious community and hospital infections, aiming to reduce hospital stays and combat resistance. Following a strategic restructuring after a 2021 regulatory setback, Iterum is now focused on the commercialization and potential label expansion of its approved asset.

Therapeutic Areas